Skip to main content

Table 1 Local and regional recurrence rates stratified by patient, tumor, and treatment characteristics

From: Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy

Characteristic

No. of Patients (%)

5-year LR (%)

HR (95%CI)

P

5-year RR (%)

HR (95%CI)

P

Age

   

0.005

  

<0.001

 >45 years

4864 (68.8)

2.2

1.000

 

3.5

1.000

 

  ≤ 45 years

2209 (31.2)

3.1

1.450 (1.118–1.879)

 

6.4

1.863 (1.492–2.325)

 

Location

   

<0.001

  

<0.001

 Other quadrants

5211 (73.7)

1.9

1.000

 

3.6

1.000

 

 Inner quadrant

1686 (23.8)

3.6

1.729 (1.303–2.293)

 

6.0

1.663 (1.305–2.120)

 

 Unknown

176 (2.5)

      

Pathologic type

   

0.210

  

0.058

 Others

893 (12.6)

1.7

1.000

 

2.9

1.000

 

 Ductal

6150 (87.0)

2.6

1.309 (0.858–1.996)

 

4.6

1.445 (0.986–2.118)

 

 Unknown

30 (0.4)

      

T stagea

   

<0.001

  

<0.001

 T1–2

6967 (98.5)

2.2

1.000

 

4.0

1.000

 

 T3–4

106 (1.5)

24.2

13.018 (8.813–19.231)

 

31.0

8.961 (6.075–13.216)

 

N stagea

   

<0.001

  

<0.001

 N0

4604 (65.1)

1.6

1.000

 

2.5

1.000

 

 N1

2142 (30.3)

2.9

1.940 (1.459–2.580)

 

5.9

2.922 (2.271–3.761)

 

 N2

173 (2.4)

9.1

5.549 (3.381–9.108)

 

12.2

6.124 (3.825–9.804)

 

 N3

154 (2.2)

17.6

14.513 (9.488–22.199)

 

33.1

18.467 (12.827–26.587)

 

No. of node dissected

   

0.035

  

0.007

  ≥ 10

6485 (91.7)

2.4

1.000

 

4.3

1.000

 

 <10

588 (8.3)

4.9

1.598 (1.029–2.481)

 

7.2

1.652 (1.145–2.384)

 

Tumor grade

   

0.001

  

0.001

 1

409 (5.8)

0

1.000

 

1.7

1.000

 

 2

3678 (52.0)

2.1

4.748 (1.171–19.244)

 

3.7

2.403 (1.062–5.440)

 

 3

1713 (24.2)

3.2

7.004 (1.715–28.607)

 

5.6

3.503 (1.534–8.001)

 

 Unknown

1273 (18.0)

      

Lymphovascular invasion

   

0.252

  

0.062

 No

6668 (94.3)

2.4

1.000

 

4.2

1.000

 

 Yes

354 (5.0)

4.7

1.357 (0.803–2.291)

 

6.9

1.507 (0.977–2.325)

 

 Unknown

51 (0.7)

      

Hormone receptor status

   

<0.001

  

<0.001

 Positive

5212 (73.7)

1.9

1.000

 

3.3

1.000

 

 Negative

1745 (24.7)

4.4

1.906 (1.467–2.476)

 

7.8

1.990 (1.585–2.498)

 

 Unknown

116 (1.6)

      

HER2 status

   

0.196

  

0.001

 Negative

4536(64.1)

2.2

1.000

 

3.8

1.000

 

 Positive

1400 (19.8)

3.1

1.241 (0.894–1.722)

 

6.5

1.564 (1.204–2.031)

 

 Unknown

1137 (16.1)

      

Ki67

   

0.553

  

0.082

  ≥ 14%

724 (10.2)

4.8

1.000

 

7.5

1.000

 

 <14%

712 (10.1)

6.1

1.143 (0.734–1.780)

 

10.2

1.378 (0.958–1.981)

 

 Unknown

5637 (79.7)

      

Molecular subtypes

       

 Luminal A

2397 (33.9)

1.3

1.000

<0.001

2.5

1.000

<0.001

 Luminal B-Her2 negative

573 (8.1)

2.6

2.132 (1.303–3.486)

 

5.3

1.920 (1.264–2.917)

 

 Luminal B-Her2 positive

810 (11.5)

3.0

1.689 (1.032–2.765)

 

5.8

1.944 (1.329–2.842)

 

 Her2-enriched

583 (8.2)

3.4

2.029 (1.231–3.343)

 

7.5

2.322 (1.564–3.447)

 

 Triple-negative

967 (13.7)

4.9

2.711 (1.842–3.991)

 

7.3

2.279 (1.626–3.194)

 

 Unknown

1743 (24.6)

      

Endocrine therapyb

   

0.075

  

0.782

 Yes

4400 (84.4)

1.4

1.000

 

2.9

1.000

 

 No

569 (10.9)

2.7

1.535 (0.954–2.470)

 

2.7

0.931 (0.563–1.541)

 

 Unknown

243 (4.7)

      

Chemotherapy

   

<0.001

  

<0.001

 No

1662 (23.5)

1.3

1.000

 

1.9

1.000

 

 Yes

5373 (76.0)

2.8

2.424 (1.561–3.765)

 

5.2

2.979 (1.993–4.451)

 

    Unknown

38 (0.5)

      

Anti-Her2 target therapyc

   

0.079

  

0.415

 Yes

321 (22.9)

1.0

1.000

 

6.1

1.000

 

 No

1067 (76.2)

3.6

2.437 (0.871–6.814)

 

6.7

1.271 (0.713–2.264)

 

 Unknown

12 (0.9)

      
  1. Abbreviations: HER2 human epidermal growth factor receptor 2
  2. a For patients who did not receive neoadjuvant chemotherapy, we used pathological stage because it is more accurate than clinical stage. For patients who received neoadjuvant chemotherapy, we used whichever stage was higher (clinical or pathological) to reflect the actual tumor burden
  3. b Only hormone-receptor positive patients included
  4. c Only Her2 positive patients included